Please login to the form below

Not currently logged in
Email:
Password:

Juniper Pharmaceuticals adds to board of directors

Mary Ann Gray joins as audit committee chair

Juniper Mary Ann GrayBoston-based Juniper Pharmaceuticals has elected Mary Ann Gray to its board of directors and appointed her as its audit committee chair.

Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals, Senomyx Inc. and TetraLogic Pharmaceuticals.

Prior to its acquisition by Shire earlier this year, Dr Gray was lead director at Dyax Corporation and has also held senior roles at the Federated Kaufmann Fund, GTC Biotherapeutics and Schering-Plough.

Jim Geraghty, Juniper's chairman, said: “Mary Ann is a highly qualified corporate director and experienced audit committee chair, and we are very pleased to have her join Juniper's board.

“Her unique blend of Wall Street, financial, and scientific experience will be a tremendous asset as Juniper continues to advance its clinical programs to drive long-term shareholder value.”

Gray succeeds Donald Hunter, who tendered his resignation from the board last year.

Geraghty added: “We deeply appreciate Don Hunter's contributions during his tenure on Juniper's board, and his willingness to provide continuity in his role as audit committee chair during our extensive search for the right person to succeed him.” 

6th April 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics